Compare Dishman Pharma with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ALKEM LABORATORIES - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ALKEM LABORATORIES DISHMAN PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x 25.1 24.2 103.9% View Chart
P/BV x 3.3 5.8 57.4% View Chart
Dividend Yield % 0.7 0.8 79.8%  

Financials

 DISHMAN PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ALKEM LABORATORIES
Mar-20
DISHMAN PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3742,720 13.8%   
Low Rs1291,660 7.8%   
Sales per share (Unadj.) Rs197.8697.9 28.3%  
Earnings per share (Unadj.) Rs21.296.1 22.1%  
Cash flow per share (Unadj.) Rs34.7117.3 29.6%  
Dividends per share (Unadj.) Rs2.0025.00 8.0%  
Dividend yield (eoy) %0.81.1 69.6%  
Book value per share (Unadj.) Rs179.9515.2 34.9%  
Shares outstanding (eoy) m80.69119.57 67.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.1 40.5%   
Avg P/E ratio x11.922.8 52.1%  
P/CF ratio (eoy) x7.218.7 38.8%  
Price / Book Value ratio x1.44.3 32.9%  
Dividend payout %9.426.0 36.3%   
Avg Mkt Cap Rs m20,306261,879 7.8%   
No. of employees `0000.814.3 5.8%   
Total wages/salary Rs m5,35515,055 35.6%   
Avg. sales/employee Rs Th19,252.75,822.6 330.7%   
Avg. wages/employee Rs Th6,459.51,050.5 614.9%   
Avg. net profit/employee Rs Th2,064.1802.0 257.4%   
INCOME DATA
Net Sales Rs m15,96183,444 19.1%  
Other income Rs m2651,042 25.5%   
Total revenues Rs m16,22684,486 19.2%   
Gross profit Rs m4,10314,734 27.8%  
Depreciation Rs m1,0912,528 43.1%   
Interest Rs m944651 145.2%   
Profit before tax Rs m2,33412,598 18.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,105 56.4%   
Profit after tax Rs m1,71111,493 14.9%  
Gross profit margin %25.717.7 145.6%  
Effective tax rate %26.78.8 304.7%   
Net profit margin %10.713.8 77.8%  
BALANCE SHEET DATA
Current assets Rs m11,01854,960 20.0%   
Current liabilities Rs m9,51732,433 29.3%   
Net working cap to sales %9.427.0 34.8%  
Current ratio x1.21.7 68.3%  
Inventory Days Days11080 138.9%  
Debtors Days Days3572 48.3%  
Net fixed assets Rs m16,30432,710 49.8%   
Share capital Rs m161239 67.5%   
"Free" reserves Rs m12,90761,368 21.0%   
Net worth Rs m14,51661,607 23.6%   
Long term debt Rs m4,1891,592 263.1%   
Total assets Rs m29,80599,433 30.0%  
Interest coverage x3.520.4 17.0%   
Debt to equity ratio x0.30 1,116.6%  
Sales to assets ratio x0.50.8 63.8%   
Return on assets %8.912.2 73.0%  
Return on equity %11.818.7 63.2%  
Return on capital %17.521.0 83.6%  
Exports to sales %24.819.1 129.9%   
Imports to sales %3.73.0 125.6%   
Exports (fob) Rs m3,95615,917 24.9%   
Imports (cif) Rs m5962,483 24.0%   
Fx inflow Rs m4,95216,061 30.8%   
Fx outflow Rs m6972,483 28.1%   
Net fx Rs m4,25513,578 31.3%   
CASH FLOW
From Operations Rs m2,7865,851 47.6%  
From Investments Rs m-1,529-7,414 20.6%  
From Financial Activity Rs m-941792 -118.9%  
Net Cashflow Rs m316-731 -43.3%  

Share Holding

Indian Promoters % 61.4 66.9 91.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 33.1 11.2%  
FIIs % 12.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 0.0 -  
Shareholders   46,261 68,381 67.7%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   PIRAMAL ENTERPRISES  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  NOVARTIS  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS